Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | 459.12% | -220.99% | |||
| Gross Profit | -459.12% | 220.45% | |||
| SG&A Expenses | 201.54% | 30.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 720.44% | -50.37% | |||
| Operating Income | -720.44% | 10.70% | |||
| Income Before Tax | -470.95% | -11.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -470.95% | -11.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -470.95% | -11.82% | |||
| EBIT | -720.44% | 10.70% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -463.33% | -15.38% | |||
| Normalized Basic EPS | -457.89% | -11.76% | |||
| EPS Diluted | -463.33% | -15.38% | |||
| Normalized Diluted EPS | -457.89% | -11.76% | |||
| Average Basic Shares Outstanding | 0.92% | -0.91% | |||
| Average Diluted Shares Outstanding | 0.92% | -0.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||